State of Tennessee Treasury Department Has $579,000 Stake in Luminex Co. (LMNX)

State of Tennessee Treasury Department trimmed its position in Luminex Co. (NASDAQ:LMNX) by 9.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,497 shares of the medical instruments supplier’s stock after selling 2,888 shares during the quarter. State of Tennessee Treasury Department owned about 0.06% of Luminex worth $579,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. GSA Capital Partners LLP lifted its stake in shares of Luminex by 74.2% in the first quarter. GSA Capital Partners LLP now owns 80,059 shares of the medical instruments supplier’s stock worth $1,687,000 after buying an additional 34,100 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Luminex by 21.6% in the first quarter. Sei Investments Co. now owns 24,073 shares of the medical instruments supplier’s stock worth $507,000 after buying an additional 4,269 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Luminex by 27.8% in the first quarter. Russell Investments Group Ltd. now owns 225,853 shares of the medical instruments supplier’s stock worth $4,759,000 after buying an additional 49,146 shares during the last quarter. Investment Management of Virginia LLC lifted its stake in shares of Luminex by 3.4% in the first quarter. Investment Management of Virginia LLC now owns 982,750 shares of the medical instruments supplier’s stock worth $20,706,000 after buying an additional 32,426 shares during the last quarter. Finally, Citigroup Inc. lifted its stake in shares of Luminex by 12.2% in the first quarter. Citigroup Inc. now owns 18,527 shares of the medical instruments supplier’s stock worth $390,000 after buying an additional 2,019 shares during the last quarter. Institutional investors and hedge funds own 81.88% of the company’s stock.

A number of equities analysts recently issued reports on the stock. BidaskClub raised shares of Luminex from a “hold” rating to a “buy” rating in a research report on Friday, May 11th. Zacks Investment Research lowered shares of Luminex from a “buy” rating to a “hold” rating in a research report on Thursday, May 10th. BTIG Research set a $26.00 target price on shares of Luminex and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Deutsche Bank raised shares of Luminex from a “sell” rating to a “hold” rating and set a $22.00 target price on the stock in a research report on Monday, May 7th. Finally, ValuEngine lowered shares of Luminex from a “buy” rating to a “hold” rating in a research report on Wednesday, May 2nd. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.00.

Shares of Luminex opened at $31.00 on Monday, Marketbeat Ratings reports. Luminex Co. has a 1 year low of $18.62 and a 1 year high of $31.17. The firm has a market cap of $1.38 billion, a P/E ratio of 38.27, a P/E/G ratio of 2.54 and a beta of 0.16.

Luminex (NASDAQ:LMNX) last announced its earnings results on Monday, May 7th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.08. Luminex had a net margin of 10.60% and a return on equity of 8.07%. The business had revenue of $82.60 million for the quarter, compared to analyst estimates of $80.52 million. During the same quarter in the previous year, the firm posted $0.28 earnings per share. Luminex’s revenue was up 6.2% compared to the same quarter last year. analysts expect that Luminex Co. will post 0.75 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 13th. Shareholders of record on Friday, June 22nd will be issued a $0.06 dividend. This represents a $0.24 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Thursday, June 21st. Luminex’s dividend payout ratio (DPR) is presently 26.37%.

In other Luminex news, SVP Todd C. Bennett sold 2,235 shares of the business’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $25.95, for a total value of $57,998.25. Following the sale, the senior vice president now owns 21,309 shares of the company’s stock, valued at approximately $552,968.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Charles J. Collins sold 17,022 shares of the business’s stock in a transaction on Thursday, May 31st. The shares were sold at an average price of $27.75, for a total transaction of $472,360.50. Following the completion of the sale, the senior vice president now directly owns 39,994 shares in the company, valued at approximately $1,109,833.50. The disclosure for this sale can be found here. Insiders sold a total of 54,699 shares of company stock worth $1,511,496 in the last three months. Insiders own 7.40% of the company’s stock.

Luminex Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply